<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00698425</url>
  </required_header>
  <id_info>
    <org_study_id>2008/Eyegate/01</org_study_id>
    <nct_id>NCT00698425</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of Transscleral Iontophoresis by the EyeGate® II Drug Delivery Device System</brief_title>
  <official_title>Single Center, Single-masked, Randomized, Dose Escalation Study to Evaluate Safety and Tolerability of Transscleral Iontophoresis Using Citrate Buffer Delivered by the EyeGate® II Drug Delivery Device System in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eyegate Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eyegate Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of a single
      iontophoretic dose of buffered solution administered through the EyeGate® II Drug Delivery
      System in healthy adult human volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, randomized, single-masked, comparative group, safety and
      tolerability study of single dose levels of citrate buffer delivered through transcleral
      iontophoresis administered via the EyeGate® II Drug Delivery System. The current study will
      also determine the safety and tolerability of the dose ranges of transcleral iontophoresis
      from 2 mA through 7 mA and will determine the safety and tolerability of the application of
      the Eyegate II system on the eye for time ranges of up to 10.5 minutes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessed through patient reported adverse events</measure>
    <time_frame>Prospective</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ophthalmic examinations</measure>
    <time_frame>Prospective</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular discomfort on a visual analog scale (VAS)</measure>
    <time_frame>Prospective</time_frame>
  </secondary_outcome>
  <number_of_arms>19</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1: 0 mA-min (0 mA for 4 min)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocular iontophoresis 0 mA-min (0 mA for 4 minutes)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: 4 mA-min (2 mA for 2 min), + polarity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocular iontophoresis 4 mA-min (2 mA for 2 minutes), positive polarity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3: 5 mA-min (2.5 mA for 2 min), +</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocular iontophoresis 5 mA-min (2.5 mA for 2 minutes), positive polarity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4: 6 mA-min (3 mA for 2 min), + polarity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocular iontophoresis 6 mA-min (3 mA for 2 minutes), positive polarity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5: 7 mA-min (3.5 mA for 2 min), +</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocular iontophoresis 7 mA-min (3.5 mA for 2 minutes), positive polarity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6: 8 mA-min (4 mA for 2 min), + polarity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocular iontophoresis 8 mA-min (4 mA for 2 minutes), positive polarity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7: 7 mA-min (3.5 mA for 2 min), -</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 mA-min (3.5 mA for 2 minutes), negative polarity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8: 8 mA-min (4 mA for 2 min), - polarity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocular iontophoresis 8 mA-min (4 mA for 2 minutes), negative polarity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9: 20 mA-min (4 mA for 5 min), +</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocular iontophoresis 20 mA-min (4 mA for 5 minutes), positive polarity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10: 20 mA-min (2 mA for 10 min), +</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocular iontophoresis 20 mA-min (2 mA for 10 minutes), positive polarity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>11: 20 mA-min (4 mA for 5 min), -</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocular iontophoresis 20 mA-min (4 mA for 5 minutes), negative polarity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12: 20 mA-min (2 mA for 10 min), -</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocular iontophoresis 20 mA-min (2 mA for 10 minutes), negative polarity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>13: 0 mA-min (0 mA for 10.5 min)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocular iontophoresis 0 mA-min (0 mA for 10.5 minutes)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>14: 13.5 mA-min (4.5 mA for 3 min), +</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocular iontophoresis 13.5 mA-min (4.5 mA for 3 minutes), positive polarity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15: 15 mA-min (5 mA for 3 min), +</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocular iontophoresis 15 mA-min (5 mA for 3 minutes), positive polarity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>16: 16.5 mA-min (5.5 mA for 3 min), +</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocular iontophoresis 16.5 mA-min (5.5 mA for 3 minutes), positive polarity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>17: 18 mA-min (6 mA for 3 min), +</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocular iontophoresis 18 mA-min (6 mA for 3 minutes), positive polarity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>18: 19.5 mA-min (6.5 mA for 3 min), +</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocular iontophoresis 19.5 mA-min (6.5 mA for 3 minutes), positive polarity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>19: 20 mA-min (7 mA for 3.84 min), +</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocular iontophoresis 20 mA-min (7 mA for 3.84 minutes), positive polarity</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EyeGate II® Drug Delivery System</intervention_name>
    <description>Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System</description>
    <arm_group_label>1: 0 mA-min (0 mA for 4 min)</arm_group_label>
    <arm_group_label>2: 4 mA-min (2 mA for 2 min), + polarity</arm_group_label>
    <arm_group_label>3: 5 mA-min (2.5 mA for 2 min), +</arm_group_label>
    <arm_group_label>4: 6 mA-min (3 mA for 2 min), + polarity</arm_group_label>
    <arm_group_label>5: 7 mA-min (3.5 mA for 2 min), +</arm_group_label>
    <arm_group_label>6: 8 mA-min (4 mA for 2 min), + polarity</arm_group_label>
    <arm_group_label>7: 7 mA-min (3.5 mA for 2 min), -</arm_group_label>
    <arm_group_label>8: 8 mA-min (4 mA for 2 min), - polarity</arm_group_label>
    <arm_group_label>9: 20 mA-min (4 mA for 5 min), +</arm_group_label>
    <arm_group_label>10: 20 mA-min (2 mA for 10 min), +</arm_group_label>
    <arm_group_label>11: 20 mA-min (4 mA for 5 min), -</arm_group_label>
    <arm_group_label>12: 20 mA-min (2 mA for 10 min), -</arm_group_label>
    <arm_group_label>13: 0 mA-min (0 mA for 10.5 min)</arm_group_label>
    <arm_group_label>14: 13.5 mA-min (4.5 mA for 3 min), +</arm_group_label>
    <arm_group_label>15: 15 mA-min (5 mA for 3 min), +</arm_group_label>
    <arm_group_label>16: 16.5 mA-min (5.5 mA for 3 min), +</arm_group_label>
    <arm_group_label>17: 18 mA-min (6 mA for 3 min), +</arm_group_label>
    <arm_group_label>18: 19.5 mA-min (6.5 mA for 3 min), +</arm_group_label>
    <arm_group_label>19: 20 mA-min (7 mA for 3.84 min), +</arm_group_label>
    <other_name>Citrate buffer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citrate buffer</intervention_name>
    <description>Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System</description>
    <arm_group_label>1: 0 mA-min (0 mA for 4 min)</arm_group_label>
    <arm_group_label>2: 4 mA-min (2 mA for 2 min), + polarity</arm_group_label>
    <arm_group_label>3: 5 mA-min (2.5 mA for 2 min), +</arm_group_label>
    <arm_group_label>4: 6 mA-min (3 mA for 2 min), + polarity</arm_group_label>
    <arm_group_label>5: 7 mA-min (3.5 mA for 2 min), +</arm_group_label>
    <arm_group_label>6: 8 mA-min (4 mA for 2 min), + polarity</arm_group_label>
    <arm_group_label>7: 7 mA-min (3.5 mA for 2 min), -</arm_group_label>
    <arm_group_label>8: 8 mA-min (4 mA for 2 min), - polarity</arm_group_label>
    <arm_group_label>9: 20 mA-min (4 mA for 5 min), +</arm_group_label>
    <arm_group_label>10: 20 mA-min (2 mA for 10 min), +</arm_group_label>
    <arm_group_label>11: 20 mA-min (4 mA for 5 min), -</arm_group_label>
    <arm_group_label>12: 20 mA-min (2 mA for 10 min), -</arm_group_label>
    <arm_group_label>13: 0 mA-min (0 mA for 10.5 min)</arm_group_label>
    <arm_group_label>14: 13.5 mA-min (4.5 mA for 3 min), +</arm_group_label>
    <arm_group_label>15: 15 mA-min (5 mA for 3 min), +</arm_group_label>
    <arm_group_label>16: 16.5 mA-min (5.5 mA for 3 min), +</arm_group_label>
    <arm_group_label>17: 18 mA-min (6 mA for 3 min), +</arm_group_label>
    <arm_group_label>18: 19.5 mA-min (6.5 mA for 3 min), +</arm_group_label>
    <arm_group_label>19: 20 mA-min (7 mA for 3.84 min), +</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults

          -  Normal ophthalmic examination in both eyes

        Exclusion Criteria:

          -  Presence of subjective ocular symptoms

          -  Presence of conjunctival hyperemia, chemosis, watering, conjunctival discharge

          -  Ocular trauma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manjoo Reddy, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Johns Medical College Hospital, Bangalore, India</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. John's Medical College Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2008</study_first_submitted>
  <study_first_submitted_qc>June 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2008</study_first_posted>
  <last_update_submitted>August 20, 2010</last_update_submitted>
  <last_update_submitted_qc>August 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Stephen From, President and Chief Executive Officer</name_title>
    <organization>Eyegate Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>Iontophoresis</keyword>
  <keyword>Ophthalmology</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

